Clinical trials of candesartan cilexetil conducted in Japan are reviewed. Candesartan cilexetil inhibited the pressor response to intravenous angiotensin II in healthy volunteers, with peak effects observed at 4 or 8 h after oral dosing; suppressing effects persisted up to 24 h. In 14 multicentre studies with 928 hypertensive patients treated for 8 to 12 weeks, candesartan cilexetil had an efficacy rate (reduction of systolic/diastolic blood pressure у20/10 mm Hg and/or mean blood pressure у13 mm Hg) of 72% and 63%, and an adverse effect rate of 9.9% and 7.3%, in patients with mild-tomoderate essential hypertension and those with impaired renal function, respectively. When data for elderly patients were analysed, there was no difference in efficacy and tolerability compared to non-elderly patients. In a double-blind comparative study, candesar-
Introduction
The renin-angiotensin system has an important role in the pathogenesis of hypertension, as well as in the maintenance of volume and electrolyte homeostasis. Many angiotensin-converting enzyme (ACE) inhibitors have been developed and are now widely used to treat hypertension or congestive heart failure. Blocking the angiotensin II (Ang II) receptor is another way to suppress the renin-angiotensin system. Ang II analogue peptides such as saralasin (Sar, 1 Ala 8 -Ang II) or sarile (Sar, 1 Ile 8 -Ang II) have been developed and used clinically for the detection of angiotensinogenic hypertension. [1] [2] [3] However, these peptides have not been used extensively because administration is limited to intravenous injection.
In the early 1980s, Furukawa et al 4 synthesised benzimidazole derivatives, such as CV-2961, which specifically blocks Ang II-induced vasoconstriction. 4 However, CV-2961 was not effective in humans because of its poor bioavailability (Ogihara et al, 1981, unpublished observation) . After the synthesis of these compounds, Timmermans et al 5 discovered DuP 753 (losartan), a potent orally active, nonpeptide Ang II receptor antagonist. 5 Candesartan cilexetil is a highly potent and longlasting AT 1 developed in Japan. 6, 7 Candesartan cilexetil is a prodrug; the active metabolite is candesartan, which is predominantly excreted into the faeces via bile. 8 The inhibiting mode of action on the AT 1 receptor has been reported to be competitive in receptor binding assays, and insurmountable in vascular contraction assays, due to its slow dissociation. 9 Preclinical experiments have revealed that candesartan cilexetil has potent and long-lasting hypotensive effects in spontaneously hypertensive, as well as in renal hypertensive, rats. 10 Prevention of hypertensive organ damage was confirmed in the brain, heart, and kidney of spontaneously hypertensive, stroke-prone (SHR-SP) and DOCA-salt rats, and candesartan cilexetil caused regression of cardiac hypertrophy without deterioration of cardiac function in spontaneously hypertensive and SHR-SP rats. 11, 12 In previous preliminary clinical studies we confirmed that candesartan cilexetil has a potent, longlasting angiotensin-antagonistic and antihypertensive action in normal volunteers and in patients with essential hypertension. [13] [14] [15] [16] In this review, we collected all data which appeared in the papers published from May 1993 to March 1998 which described the results of clinical trials conducted in Japan to evaluate the efficacy and tolerability of candesartan cilexetil in patients with hypertension.
Inhibition of Ang II effects by candesartan cilexetil
At 1 mg, 2.5 mg, and 5 mg, candesartan cilexetil dose-dependently inhibited the pressor response to T Ogihara and K Arakawa S28 intravenous infusion of Ang II (2.5-40 ng/kg per min for 5 min each) in five healthy male volunteers after single oral doses given on separate days at 1-week intervals. 17 The peak effects were obtained at 4 or 8 h after dosing, and the suppressing effects persisted up to 24 h. The pressor response was reduced by 33%, 50%, and 60% at 24 h after a single dose of candesartan cilexetil at 1 mg, 2.5 mg, and 5 mg, respectively ( Figure 1a ). Delacretaz et al 18 also reported that candesartan cilexetil inhibited the pressor response to exogenous Ang II in normal volunteers after single and multiple oral doses of 1 to 8 mg.
Candesartan cilexetil had no effects on basal plasma aldosterone concentrations. However, a single 5-mg dose suppressed the response of aldosterone to exogenous Ang II to 48% for up to 24 h 19 ( Figure 1b) . These results suggest that candesartan cilexetil is a highly potent and long-lasting antagonist of Ang II in humans. 
Effects of candesartan cilexetil on diurnal variations of blood pressure
Twenty-eight hospitalised patients with mild to moderate essential hypertension (mean age, 56 ± 13 years, mean ± s.d.) were treated with 1-8 mg of candesartan cilexetil daily for 3-20 days. Blood pressure (BP) was monitored every 2 h up to 13 and at 24 h (trough point) after final administration. BP at each time point was significantly reduced compared with those of the placebo run-in period. 15 The longlasting hypotensive effects were also confirmed by monitoring the ambulatory BP for 24 h. Heuer et al 19 showed that a daily dose of 4 to 16 mg of candesartan cilexetil reduced daytime and night-time ambulatory BP compared with placebo at weeks 6 and 12 without affecting circadian BP variations. In this study, they estimated the trough/peak ratio of candesartan cilexetil to be 80% over the dose range of 8 to 16 mg.
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Efficacy of candesartan cilexetil in hypertensive patients in relation to dose
The safety and tolerability of candesartan cilexetil, both as monotherapy and in combinations with other antihypertensive agents, except ACE inhibitors, have been evaluated in 14 multicentre studies with a duration of up to 12 weeks and in some longterm studies with a duration of 52 weeks for 928 hypertensive patients. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The dose-related efficacy, defined as a reduction of systolic BP (SBP)/diastolic BP (DBP) у20/10 mm Hg and/or mean BP у13 mm Hg compared to basal BP in the placebo run-in period, as well as the incidence of side effects (subjective or objective adverse events and complications) are shown in Tables 1 and 2 . Each study was conducted using mostly out-patients with hypertension. After a 4-week placebo run-in period, treatment with candesartan cilexetil was started at 2 mg once daily and titrated to 12 mg once daily at 2-to 4-week intervals until sufficient BP reduction (у20 mm Hg in SBP and у10 mm Hg in DBP and/or у13 mm Hg in mean S29 BP) was obtained. The total treatment period was 8 to 12 weeks; in the long-term studies, the treatment period was extended up to 52 weeks. The sitting BP and pulse rate were determined every 2 or 4 weeks. In 847 patients with mild to moderate essential hypertension (WHO I or II), the efficacy increased dose-dependently to 73% and 72% by monotherapy and by combination therapy, respectively. The incidence of side effects was 9.9% in the majority of patients who had been on a 2-12 mg once-daily treatment for 8-12 weeks (Table 1 ). The long-term efficacy rate in 262 patients treated from more than 6 months up to 12 months was 82%, and the incidence of side effects was 9.5%. The adverse reactions were mild, and no serious reactions were reported. [20] [21] [22] [23] [24] [25] In patients with severe hypertension whose DBP was 110 mm Hg or greater while taking at least one antihypertensive drug other than ACE inhibitors, the cumulative efficacy was 28%, 58%, and 78% with a once-daily treatment of candesartan cilexetil at 4 mg, 8 mg, and 12 mg, respectively. 26 In patients with renal failure, the efficacy was 63% and the incidence of side effects was 7.3%. 27 All 928 patients included in these studies were stratified into two age groups, non-elderly (р64 years old) and elderly (у65 years old) patients, and efficacy and tolerability were evaluated. The cumulative efficacy rates were very similar for both groups, and the final efficacy rate at 12 mg was 72% in both groups. The incidence of side effects was 9.2% in the non-elderly group and 11.6% in the elderly group. Thus, there was no difference in efficacy and tolerability between the two groups. We concluded, based on these results, that candesartan cilexetil is a safe and useful antihypertensive drug at a dose of 4 -8 mg once daily for the treatment of hypertension including severe, renal hypertension, and hypertension occurring in the elderly. Dosedependent antihypertensive effects of with candesartan cilexetil were also confirmed by a metaanalysis of six randomised, double-blind, placebocontrolled European studies involving 1482 patients at a dose range of 2-16 mg daily for a treatment period of up to 12 weeks. 34 It is well known that ACE inhibitors exhibit sufficient antihypertensive effects even in the elderly. 35 The results of the present and previous 28 analyses in Japanese studies show nearly similar cumulative dose-response efficacy in both non-elderly and elderly patients. McInnes et al 36 reported the efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population, indicating that the antihypertensive effects of candesartan cilexetil were not markedly influenced by age. They also showed that 8 or 16 mg of candesartan cilexetil daily was equally well tolerated by elderly and younger patients treated for 12 weeks. 36 Both the present analysis and reports by McInnes et al 36 show the usefulness of candesartan cilexetil in the treatment of hypertension in the elderly.
Results of a double-blind comparative study with candesartan cilexetil and enalapril
The efficacy and safety of candesartan cilexetil in patients with essential hypertension were evaluated by a double-blind, comparative study using enalapril maleate as a control drug. 29 The study was conducted with a daily titrating dosage of candesartan cilexetil from 4 mg to 8 mg and 12 mg, and that of enalapril from 5 mg to 10 mg and 20 mg in a 12-week treatment period.
Patients taking candesartan cilexetil (n = 134) and patients taking enalapril (n = 128) were evaluated. The efficacy rate of candesartan cilexetil was higher (73.9%) than that of enalapril (66.4%). Table 3 shows that the incidence of adverse reactions in the candesartan cilexetil treatment group (10.4%) was 29 significantly lower than that in the enalapril group (27.3%, P Ͻ 0.01). The incidence of coughing was significantly lower in the candesartan cilexetil group (1.5%) than the enalapril group (14.8%, P Ͻ 0.01).
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The incidence of abnormal laboratory tests were not significantly different between the two groups. On the overall safety rating, the study treatment was shown to be safe in 76.1% of the patients taking candesartan cilexetil and 64.1% of those taking enalapril (P Ͻ 0.05).
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In European studies, double-blind randomised clinical trials of 8-12 weeks' duration showed that 4 -16 mg of candesartan cilexetil had efficacy at least comparable to that of other antihypertensive drugs such as ACE inhibitors; 37, 38 an Ang II antagonist, losartan; 39 and a calcium antagonist, amlodipine.
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Target organ protection with candesartan cilexetil
Candesartan cilexetil appears to improve or preserve renal function in patients with essential hypertension. Ise et al 41 showed that 4 -8 mg of candesartan cilexetil daily caused no changes in renal function indices during a 2-week treatment. In some patients these findings were maintained for 6 months. 41 In a study using 2-8 mg of candesartan cilexetil daily for hypertensive patients with impaired renal function whose pretreatment serum creatinine levels were between 1.5-4.0 mg/dl, the mean serum creatinine level did not change significantly (from 1.84 ± 0.96 to 1.86 ± 0.91 mg/dl) during the 2-to 8-week treatment. 42 Preclinical studies suggest that candesartan cilexetil has a cardioprotective effect and is also effective in the prevention and regression of left ventricular hypertrophy (LVH). 10, 11 The effect of candesartan cilexetil on regression of LVH has been confirmed in short-term clinical trials. Echocardiography and cine-MRI examination show that treatment with 2-12 mg of candesartan cilexetil once daily for 12 to 24 weeks reduced left ventricular weight by 7.7% to 9.3% in patients with mild to moderate essential hypertension.
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Conclusions
Candesartan cilexetil is a well tolerated and highly effective antihypertensive drug in a wide range of patients with hypertension. A dose of 4 to 8 mg once a day seems to be appropriate. Its improved tolerability profile over ACE inhibitors, as well as its characteristics for end-organ protective effects, suggests that candesartan cilexetil is useful as a firstline antihypertensive drug.
